Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (ANIK) is a publicly traded US company. Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

The company reports trailing twelve-month revenue of $29.61M and net loss of $5.06M.

Key metrics include a return on equity of -3.8%.

Investors tracking ANIK can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.